Qian Zhao

Qian Zhao


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2015 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
QZQian Zhao
Qian Zhao
PLPingya Li
Pingya Li
JJJi Jiang
Ji Jiang
PHPei Hu
Pei Hu

15 May 2022 in Journal of Chromatography B
Verified
Journal Article
Closed access
XZXin Zheng
Xin Zheng
XCXia Chen
Xia Chen
TLTao Liu
Tao Liu
JJJi Jiang
Ji Jiang
XCXinge Cui
Xinge Cui
PHPei Hu
Pei Hu

17 November 2012 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
XCXia Chen
Xia Chen
PHPei Hu
Pei Hu
JJJi Jiang
Ji Jiang
TLTao Liu
Tao Liu
WZWen Zhong
Wen Zhong
QZQian Zhao
Qian Zhao

19 April 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HWHuanhuan Wang
Huanhuan Wang
XHXiaoyun Hu
Xiaoyun Hu
TWTeng Wang
Teng Wang
CCCheng Cui
Cheng Cui
JJJi Jiang
Ji Jiang
PHPei Hu
Pei Hu
Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa clinical trial were used in the model: 10 sepsis patients from the placebo group and a total of 24 sepsis patients from the 0.06 mg/kg, 0.12 mg/kg, and 0.24 mg/kg drug groups. Exposure-response relationship was constructed to model the impact of the standard care therapy and area under curve (AUC) of kukoamine B to the disease biomarker (SOFA score). The model was evaluated by goodness of fit and visual predictive check. The simulation was performed 1,000 times based on the built model.Results: The data of the placebo and the drug groups were pooled and modeled by a nonlinear mixed-effect modeling approach in sepsis. A latent-variable approach in conjunction with an inhibitory indirect response model was used to link the standard care therapy effect and drug exposure to SOFA score. The maximum fraction of the standard care therapy was estimated to 0.792. The eliminate rate constant of the SOFA score was 0.263/day for the standard care therapy. The production rate of SOFA score (Kin) was estimated at 0.0569/day and the AUC at half the maximal drug effect (EAUC50) was estimated at 1,320 h*ng/mL. Model evaluation showed that the built model could well describe the observed SOFA score. Model-based simulations showed that the SOFA score on day 7 decreased to a plateau when AUC increased to 1,500 h*ng/mL.Conclusion: We built an exposure-response model characterizing the pharmacological effect of kukoamine B from the standard care therapy in sepsis patients. A dose regimen of 0.24 mg/kg was finally recommended for the Phase IIb clinical trial of kukoamine B based on modeling and simulation results.

1 February 2018 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CCCheng Cui
Cheng Cui
PHPei Hu
Pei Hu
JJJi Jiang
Ji Jiang
FKFansheng Kong
Fansheng Kong
HLHong Luo
Hong Luo
QZQian Zhao
Qian Zhao

24 September 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SYShuangqing Yu
Shuangqing Yu
QZQian Zhao
Qian Zhao
CZCengceng Zhang
Cengceng Zhang
DFDiyi Fu
Diyi Fu
XZXueYang Zhu
XueYang Zhu
XDXiaoyan Dong
Xiaoyan Dong
Anti-AAV neutralizing Abs (NAbs) titer is usually measured by cell-based microneutralization (MN) assay and is crucial for patient screening in AAV-based gene therapy clinical trials. However, achieving uniform operation and comparable results among different laboratories remains challenging. Here, we established a standardized MN assay for anti-AAV9 NAbs in human sera or plasma and transferred the method to the other two research teams. Then, we validated its parameters and tested a set of eight human samples in blind across all laboratories. The end-point titer, defined by a transduction inhibition of 50% (IC50), was calculated using curve-fit modelling. A mouse neutralizing monoclonal antibody in human negative serum was used for system quality control (QC), requiring inter-assay titer variation of <4-fold difference or geometric coefficient of variation (%GCV) of <50%. The assay demonstrated a sensitivity of 54 ng/mL and no cross-reactivity to 20 μg/mL anti-AAV8 MoAb. The intra-assay and inter-assay variation for the low positive QC were 7–35% and 22–41%, respectively. The titers of the blind samples showed excellent reproducibility within and among laboratories, with a %GCV of 18–59% and 23–46%, respectively. This study provides a commonly transferrable MN assay for evaluating anti-AAV9 NAbs in humans, supporting its application in clinical trials.